Cargando…
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197365/ https://www.ncbi.nlm.nih.gov/pubmed/34073911 http://dx.doi.org/10.3390/ijms22115536 |